Your browser doesn't support javascript.
loading
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France.
Loubet, Paul; Gaborit, Benjamin; Salpin, Mathilde; Gardeney, Hèlene; Benotmane, Ilies; Systchenko, Thomas.
Affiliation
  • Loubet P; Virulence Bactérienne et Infections Chroniques, University Montpellier, Nîmes, France.
  • Gaborit B; Service des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, France.
  • Salpin M; Service de Pneumologie, AP-HP, Hôpital Bichat, Paris, France.
  • Gardeney H; Service d'Hématologie, CHU Poitiers, Poitiers, France.
  • Benotmane I; Service de Néphrologie-Dialyse-Transplantation, CHU Strasbourg, Strasbourg, France.
  • Systchenko T; Service d'Hématologie, CHU Poitiers, Poitiers, France.
Hum Vaccin Immunother ; 20(1): 2387221, 2024 Dec 31.
Article in En | MEDLINE | ID: mdl-39143811
ABSTRACT
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunocompromised Host / Pre-Exposure Prophylaxis / COVID-19 Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Hum Vaccin Immunother Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunocompromised Host / Pre-Exposure Prophylaxis / COVID-19 Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Hum Vaccin Immunother Year: 2024 Document type: Article Affiliation country: Country of publication: